Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients

Pharmacogenomics Journal

Volumn 8, Issue 3, 2008, Pages 174-185

  Sandanaraj, E ^a   Jada, S R ^a   Shu, X ^a   Lim, R ^b   Lee, S C ^b   Zhou, Q ^a   Zhou, S ^c   Goh, B C ^b   Chowbay, B ^a  

^a Humphrey Oei Institute of Cancer Research   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CYTOSINE; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; THYMINE;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; ASIAN; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG GLUCURONIDATION; DRUG INFUSION; ETHNOPHARMACOLOGY; FEMALE; GASTROINTESTINAL TUMOR; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; INTRON; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC THERAPY; UROGENITAL TRACT TUMOR;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; INTRONS; LIVER; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 44049095766     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500473     Document Type: Article

References (31)

1. Dutton GJ. Glucuronidation of drugs and other compounds. CRC Press: Boca Raton, FL, 1980.
2. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: Metabolism, expression and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
3. Owens IS, Ritter JK. Gene structure at the human UGT1 locus creates diversity in isozyme structure, structure specificity and regulation. Prog Nucleic Acid Res 1995; 51: 306-308.
4. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK et al. Thirteen UDP glucuronosyltransferases genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11: 357-368.
5. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-899.
6. Harding D, Fournel-Gigleux S, Jackson MR, Burchell B. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. Proc Natl Acad Sci USA 1988; 85: 8381-8385.
7. Ritter JK, Crawford JM, Owens IS. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. J Biol Chem 1991; 266: 1043-1047.
8. Wooster R, Sutherland L, Ebner T, Clarke D, Da Cruz e Silva O, Burchell B. Cloning and stable expression of a new member of the human liver phenol/bilirubin:UDP-glucuronosyltransferase cDNA family. Biochem J 1991; 278: 465-469.
9. Mojarabbi B, Butler R, Mackenzie PI. cDNA cloning and characterization of the human UDP-glucuronosyltranbsferase, UGT1A3. Biochem Biophys Res Commun 1996; 225: 785-790.
10. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. Differential expression of the UGT1A locus in human liver, biliary and gastric tissue. Identification if UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 1997; 52: 212-220.
11. Strassburg CP, Manns MP, Tukey RH. Expression of UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of novel extrahepatic UGT1A8. J Biol Chem 1998; 273: 8719-8726.
12. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
13. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumour effect of CPT-11. Cancer Res 1991; 51: 4187-4191.
14. Rivory LP, Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995; 36: 176-179.
15. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997; 80: 91-96.
16. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A et al Identification and properties of a major plasmametabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996; 56: 3689-3694.
17. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation of SN-38. J Pharmacol Exp Ther 1998; 286: 578-583.
18. Rivory LP. Metabolism of CPT-11. Impact on activity. Ann NY Acad Sci 2000; 922: 205-215.
19. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
20. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T et al. UGT1A1*28 polymorphism as a determinant or irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
21. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-617.
22. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 2005; 11: 1226-1236.
23. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068.
24. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-515.
25. Kitagawa C, Ando M, Ando Y, Sekido Y, Wakai K, Imaizumi K et al. Genetic polymorphism in the Phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15: 35-41.
26. Villeneuve L, Girard H, Fortier LC, Gagne IF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 74-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307: 117-128.
27. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q et al Identification of common polymorphisms in the promoter of the UGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14 501-515.
28. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita et al A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14: 329-332.
29. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q et al The novel UGT1A9 intronic 1399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 2006; 34: 1220-1228.
30. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J et al. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14: 329-332.
31. Han J-Y, Lim H-.S, Shin ES, Yoo Y-K, Park YH, Lee Y-E et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 15: 2237-2244.